Clinical Training Update: LISINOPRIL HCTZ
=========================================

TO: All Clinical Staff
FROM: Medical Education Department
DATE: September 14, 2025
SUBJECT: Important Clinical Update - LISINOPRIL HCTZ

BACKGROUND:
This memo provides important updates regarding LISINOPRIL HCTZ that affect current
clinical protocols and patient care procedures.

CURRENT PROTOCOLS:
• Current dosing guidelines: Standard dosing per label
• Monitoring requirements: Standard warnings
• Indications for use: As approved

CLINICAL CONSIDERATIONS:
Staff should be aware that current protocols for LISINOPRIL HCTZ are based on
Standard warnings. 

Patient population affected: Patients similar to case: 1, age 58
Risk level: Medium
Contraindications: Enhanced screening for risk factors

ADVERSE EVENTS TO MONITOR:
Hypertension, Dehydration, Night sweats

MECHANISM OF ACTION:
LISINOPRIL HCTZ mechanism with identified safety concern

THERAPEUTIC CLASS:
Adverse Event Report

COMPLIANCE REQUIREMENTS:
All staff must review and acknowledge this update by 2025-10-14.

QUESTIONS:
Contact the Medical Education Department with any questions or concerns
regarding these clinical updates.

---
Medical Education Department
Internal Distribution Only
Document ID: MED-2812
Revision Date: September 2024
